Brind.

Amgen acquired Five Prime Therapeutics for $1.9 billion, and Carol A. Schafer was appointed to boards at Kura Oncology and OMass Therapeutics.

1 report, 1 independent Updated Aug 6

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AmgenFive Prime Therapeutics (United States)Kura Oncology

Keep exploring

The entities involved

Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
Kura Oncology
company in La Jolla, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 6GlobeNewswireOMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair